Cannabis abstinence and thinking skills in 15–18-year-olds
Official title: Cannabis Abstinence and Neurocognitive Assessment in Adolescence
Run by University Hospital Pilsen · NCT07160153 · Data updated 2026-11-12
We will test whether stopping cannabis use leads to improved thinking and memory in 15–18-year-olds with cannabis dependence or harmful use, with abstinence verified by urine tests.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 15 Years to 18 Years |
| Sex | All |
| Enrollment | 29 (estimated) |
| Sponsor | University Hospital Pilsen Academic / other |
| Locations | 1 site (Pilsen, Czechia) |
| Status | Recruiting |
| Started | December 3, 2024 |
| Main results expected | December 31, 2028 |
| Study ends | August 31, 2029 |
| Registry record updated | November 2, 2026 |
| Trial ID | NCT07160153 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adolescents aged 15–18 diagnosed with cannabis dependence or harmful cannabis use who can provide urine-confirmed abstinence and do not have excluded psychiatric or severe somatic comorbidities are ideal candidates.
✕Probably not a fit
Patients with dual diagnoses such as psychotic or severe mood disorders, major organic brain damage, autism spectrum disorder, severe somatic disease, or those unable to maintain abstinence are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study follows adolescents aged 15–18 who have cannabis dependence or harmful cannabis use and measures neurocognitive function before and after confirmed abstinence. Participants undergo standardized neuropsychological testing and urine toxicology to verify abstinence between assessments. The study excludes those with major psychiatric disorders (except stabilized anxiety), severe somatic illnesses, or those who violate abstinence or require major medication changes. Psychotropic medications are allowed except antipsychotics for psychosis, and all testing is conducted at a single hospital site in Pilsen, Czechia.
Why it matters
Potential benefit: If successful, the results could clarify whether cognitive functions recover after cannabis abstinence in adolescents and help guide timing and focus of treatments.
How similar studies have gone: Prior research has shown mixed but promising evidence that some cognitive deficits after cannabis use can improve with sustained abstinence, so this study builds on but does not radically depart from existing findings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use. Exclusion Criteria: * psychiatric comorbidity - Dual diagnosis, including psychotic disorders, mood disorders, severe organic brain damage, or autism spectrum disorder, with the exception of compensated and stabilized anxiety disorder. Psychopharmacological treatment is permitted, except for antipsychotics prescribed for psychosis. * somatic comorbidity - Severe endocrine disorders such as diabetes mellitus, thyroid dysfunction, or severe cardiovascular disease. * Violation of abstinence between the first and second neuropsychological assessments, as well as severe decompensation of mental state requiring modification of established psychopharmacological treatment.
Where it's running
-
University Hospital Pilsen
Pilsen, Czechia, Czechia Recruiting
Study contacts
- Study coordinator: Jiri Podlipny, MD, Ph.D.
- Email: podlipny@fnplzen.cz
- Phone: +420 377 103 209
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Mushroom powder to slow cognitive decline in middle-aged and younger seniors
A randomized trial will test whether daily golden oyster mushroom powder helps maintain cognitive function in adults aged 45–80 who have a family history of dementia or subjective memory concerns.
-
Semaglutide for cannabis use disorder: see if a medicine helps reduce use
This study tests whether weekly injections of semaglutide can help adults with cannabis use disorder reduce their cannabis use compared with placebo.
-
Pecan or Pretzel Snacks for Brain Health in Adults 50+
This study tests whether daily pecan or pretzel snacks for three months can improve memory and mood in people aged 50 and older with cognitive impairment.
-
Brain imaging to predict teens' response to cannabis treatment
This project will test whether teens' brain activity during a learning task can predict how well 14–17-year-olds do in a 10-week virtual reward program to reduce cannabis use.
-
Think Tank nutritional drink to help thinking after stress in middle-aged women.
This trial will test whether taking the 'Think Tank' nutritional drink helps thinking and mood after a physical and psychological stressor in healthy women aged 40–60 who drink caffeine daily.
-
How alcohol changes the social brain during paired interactions
This study tests whether drinking alcohol changes brain activity and social bonding during conversations between pairs of regular social drinkers aged 21–30.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.